Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease

The Journal of Clinical Endocrinology & Metabolism(2022)10.1210/clinem/dgac168Source: DataRank Database

Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease is a research paper published in The Journal of Clinical Endocrinology & Metabolism (2022). On theSindex it has a DataRank of 0. It has been cited 28 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access28 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 3.13)OA: hybridTopics (36)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Raymond S. Douglas ORCID,Chrysoula Dosiou ORCID,Andrea L. Kossler ORCID

Live enrichment

PubMed:36346685 PMC:PMC9359446 OpenAlex:https://openalex.org/W4290673638

National Institutes of Health

Grant: P30 026877

NEI NIH HHS

Grant: P30 EY026877

National Institutes of Health

Grant: 2P30EY026877-06

Stanford Vision Research Core

FWCI

3.13

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://academic.oup.com/jcem/article-pdf/107/Supplement_1/S36/46873435/dgac168.pdf

publisherhttps://academic.oup.com/jcem/article-pdf/107/Supplement_1/S36/46873435/dgac168.pdf

journalhttps://doi.org/10.1210/clinem/dgac168

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36346685

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9359446

Fields of Study

Ophthalmology and Eye DisordersThyroid Disorders and TreatmentsConnexins and lens biology03 medical and health sciences0302 clinical medicineHumansGraves OphthalmopathyAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalImmunosuppressive Agents

MeSH Terms

Antibodies, MonoclonalHumansImmunosuppressive AgentsGraves OphthalmopathyAntibodies, Monoclonal, Humanized

Keywords

MedicineContext (archaeology)Intensive care medicineDiseaseAdverse effectThyroidGraves' ophthalmopathyGraves' diseaseClinical trialInternal medicineManagementTargeted TherapyGraves OphthalmopathyBiologic TherapyThyroid Eye DiseaseTeprotumumabHumansAntibodies, MonoclonalSupplement ArticlesAntibodies, Monoclonal, HumanizedImmunosuppressive Agents

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Partnerships for the goals